Replies to post #98155 on Biotech Values

[DewDiligence]

From the 5/24/10 issue of The Pink Sheet (#msg-50845618):

During an interview, [DNDN’s COO Hans] Bishop also elaborated on the comparative figures for widely used cancer treatments that Dendreon considered in its pricing process. The standard of care in late-stage prostate cancer is Sanofi's chemotherapy treatment Taxotere. Direct per-patient costs for Taxotere amount to only $18,000 per patient, but when indirect costs are included, such as supportive care, the total is actually about $60,000, according to Dendreon.